These results suggest that some unique feature(s) of the KRAS Q61H mutant can render cancer cells independent of SHP2 function(s) and therefore resistant to pharmacologic (or molecular) inhibition of SHP2, unlike cells with WT-KRAS or the more common codon 12 mutations. Here, KRAS is linked to cancer.